Repigmentation of vitiligo during efalizumab

Saved in:
Bibliographic Details
Published inJournal of the American Academy of Dermatology Vol. 59; no. 2; pp. S57 - S58
Main Authors Wakkee, Marlies, MD, Assen, Yvette J., MD, Thio, H. Bing, MD, PhD, Neumann, H. A. Martino, MD, PhD
Format Journal Article
LanguageEnglish
Published New York, NY Mosby, Inc 01.08.2008
Elsevier
Subjects
Antibodies, Monoclonal - therapeutic use
Biological and medical sciences
Dermatology
Humans
Male
Medical sciences
Middle Aged
Pigmentary diseases of the skin
Psoriasis - complications
Psoriasis - drug therapy
Skin Pigmentation - drug effects
Vitiligo - complications
Vitiligo - drug therapy
Vitiligo - pathology
Immunomodulator
Skin disease
Vitiligo
Pigmentation disorder
Dermatology
Antipsoriatic agent
Monoclonal antibody
Efalizumab
Online AccessGet full text

Cover

More Information
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2008.03.032